Pricing Log in Create free account
Friday 6 November 2026 Export HAE’s income statement to Excel — free account

Haemonetics Corporation

HAE Healthcare Medical Devices

Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025.

Revenue
+9.30%
EPS
+25.9%
Free cash flow
+20.4%
Total debt
+21.0%

Quarter to September 2026, against a year earlier

119.97 4.14 −3.34%
Market cap
$5.7B
P/E
54.5×
Fwd P/E
30.2×
Dividend yield
—
F-score
6/9
Altman Z
2.21
Beneish M
−2.81
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Haemonetics Corporation (HAE) EV/EBITDA

Alert me on EV/EBITDA

As of 5 November 2026, Haemonetics Corporation (HAE) trades at a EV/EBITDA of 23.6×. Over the past ten years it has ranged from 8.0× (October 2025) to 62.2× (September 2016); the current reading is higher than 59% of that period. That is above the Medical Devices industry median of 11.5× and above the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2026 13.2× 22.42%
FY2025 10.8× (41.59%)
FY2024 18.5× (1.12%)
FY2023 18.7× (3.37%)
FY2022 19.4× (44.73%)
FY2021 35.1× 43.97%
FY2020 24.4× (1.60%)
FY2019 24.8× (2.32%)
FY2018 25.4× (19.10%)
FY2017 31.3× (29.05%)

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 20.6× 29.82%
Jun 2026 15.9× 19.89%
Mar 2026 13.2× 14.46%
Dec 2025 11.6× 44.47%
43 more quarters

Against its own ten years

Low 8.0× High 62.2×
Ten-year median 20.8×
Current reading's percentile 59

EV/EBITDA against peers

Company EV/EBITDA
BIO Bio-Rad Laboratories, Inc. compare n/m
AXGN AxoGen, Inc. compare n/m
TXG 10x Genomics compare n/m
BIO.B Bio-Rad Laboratories, Inc. compare n/m
LIVN LivaNova PLC compare 17.6×
ITGR Integer Holdings Corporation compare 18.8×
HAE Haemonetics Corporation 23.6×
BRKR Bruker Corporation compare 66.0×
IRTC iRhythm Holdings, Inc. compare 2,944×
Medical Devices industry median 11.5×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on HAE